C WorldWide Group Holding A S increased its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 25.2% during the second quarter, Holdings Channel reports. The institutional investor owned 241,505 shares of the biotechnology company’s stock after buying an additional 48,618 shares during the period. C WorldWide Group Holding A S’s holdings in Coherus BioSciences were worth $3,466,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its position in Coherus BioSciences by 20.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 161,366 shares of the biotechnology company’s stock valued at $2,316,000 after buying an additional 27,064 shares in the last quarter. Boston Advisors LLC bought a new position in Coherus BioSciences during the second quarter valued at about $244,000. Handelsbanken Fonder AB boosted its position in Coherus BioSciences by 22.2% in the second quarter. Handelsbanken Fonder AB now owns 55,000 shares of the biotechnology company’s stock valued at $789,000 after buying an additional 10,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Coherus BioSciences by 239.6% in the first quarter. Goldman Sachs Group Inc. now owns 141,095 shares of the biotechnology company’s stock valued at $2,984,000 after buying an additional 99,548 shares in the last quarter. Finally, Credit Suisse AG boosted its position in Coherus BioSciences by 15.4% in the first quarter. Credit Suisse AG now owns 164,113 shares of the biotechnology company’s stock valued at $3,472,000 after buying an additional 21,958 shares in the last quarter. Institutional investors and hedge funds own 72.07% of the company’s stock.

Shares of Coherus BioSciences, Inc. (CHRS) opened at 11.65 on Friday. Coherus BioSciences, Inc. has a one year low of $10.80 and a one year high of $31.98. The stock’s market capitalization is $598.18 million. The firm’s 50-day moving average is $13.61 and its 200-day moving average is $19.60.

Coherus BioSciences (NASDAQ:CHRS) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.29) by $0.21. The business had revenue of $1.40 million during the quarter. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. Equities research analysts forecast that Coherus BioSciences, Inc. will post ($5.13) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Coherus BioSciences, Inc. (CHRS) Shares Bought by C WorldWide Group Holding A S” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/12/coherus-biosciences-inc-chrs-shares-bought-by-c-worldwide-group-holding-a-s.html.

Several research firms have issued reports on CHRS. J P Morgan Chase & Co restated an “overweight” rating and set a $25.00 target price (down previously from $32.00) on shares of Coherus BioSciences in a research note on Tuesday. BidaskClub lowered shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Credit Suisse Group reissued an “outperform” rating and issued a $24.00 target price (down from $38.00) on shares of Coherus BioSciences in a report on Wednesday, June 14th. ValuEngine lowered shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a report on Tuesday, June 13th. Finally, Citigroup Inc. reduced their target price on shares of Coherus BioSciences from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, June 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $35.90.

In other news, insider Alan C. Herman sold 17,535 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $15.02, for a total transaction of $263,375.70. Following the completion of the transaction, the insider now directly owns 49,651 shares of the company’s stock, valued at approximately $745,758.02. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 32.88% of the company’s stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRS).

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.